Search Results - "Núria Chic"

Frequency and spectrum of PIK3CA somatic mutations in breast cancer by Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix

“…The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced…”
Get full text

Biomarkers of immunotherapy response in breast cancer beyond PD-L1 by Chic, Nuria, Brasó-Maristany, Fara, Prat, Aleix

“…Immune checkpoint inhibitors have modified the treatment algorithm in a variety of cancer types, including breast cancer. Nevertheless, optimal selection of…”
Get full text

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial by Prat, Aleix, Saura, Cristina, Pascual, Tomás, Hernando, Cristina, Muñoz, Montserrat, Paré, Laia, González Farré, Blanca, Fernández, Pedro L, Galván, Patricia, Chic, Núria, González Farré, Xavier, Oliveira, Mafalda, Gil-Gil, Miguel, Arumi, Miriam, Ferrer, Neus, Montaño, Alvaro, Izarzugaza, Yann, Llombart-Cussac, Antonio, Bratos, Raquel, González Santiago, Santiago, Martínez, Eduardo, Hoyos, Sergio, Rojas, Beatriz, Virizuela, Juan Antonio, Ortega, Vanesa, López, Rafael, Céliz, Pamela, Ciruelos, Eva, Villagrasa, Patricia, Gavilá, Joaquín

“…In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine…”
Get full text

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix

“…Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of…”
Get full text

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis by Schettini, Francesco, Pascual, Tomás, Conte, Benedetta, Chic, Nuria, Brasó-Maristany, Fara, Galván, Patricia, Martínez, Olga, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Fernández-Martinez, Aranzazu, Rognoni, Carla, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco, Locci, Mariavittoria, Brase, Jan C., Gonzalez-Farre, Blanca, Villagrasa, Patricia, De Placido, Sabino, Schiff, Rachel, Veeraraghavan, Jamunarani, Rimawi, Mothaffar F., Osborne, C. Kent, Pernas, Sonia, Perou, Charles M., Carey, Lisa A., Prat, Aleix

“…•We correlated the breast cancer intrinsic subtypes with pCR in HER2+ disease.•The HER2-E subtype was significantly and consistently associated with pCR after…”
Get full text

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation by Prat, Aleix, Guarneri, Valentina, Paré, Laia, Griguolo, Gaia, Pascual, Tomás, Dieci, Maria V, Chic, Núria, González-Farré, Blanca, Frassoldati, Antonio, Sanfeliu, Esther, Cejalvo, Juan M, Muñoz, Montserrat, Bisagni, Giancarlo, Brasó-Maristany, Fara, Urso, Loredana, Vidal, Maria, Brandes, Alba A, Adamo, Barbara, Musolino, Antonino, Miglietta, Federica, Conte, Benedetta, Oliveira, Mafalda, Saura, Cristina, Pernas, Sònia, Alarcón, Jesús, Llombart-Cussac, Antonio, Cortés, Javier, Manso, Luis, López, Rafael, Ciruelos, Eva, Schettini, Francesco, Villagrasa, Patricia, Carey, Lisa A, Perou, Charles M, Piacentini, Federico, D'Amico, Roberto, Tagliafico, Enrico, Parker, Joel S, Conte, Pierfranco

“…In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial topic. As an aid to treatment decisions, we…”
Get full text

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade by Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

“…The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20–60% of HER2+/HER2-E tumors…”
Get full text

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer by Prat, Aleix, Brasó-Maristany, Fara, Martínez-Sáez, Olga, Sanfeliu, Esther, Xia, Youli, Bellet, Meritxell, Galván, Patricia, Martínez, Débora, Pascual, Tomás, Marín-Aguilera, Mercedes, Rodríguez, Anna, Chic, Nuria, Adamo, Barbara, Paré, Laia, Vidal, Maria, Margelí, Mireia, Ballana, Ester, Gómez-Rey, Marina, Oliveira, Mafalda, Felip, Eudald, Matito, Judit, Sánchez-Bayona, Rodrigo, Suñol, Anna, Saura, Cristina, Ciruelos, Eva, Tolosa, Pablo, Muñoz, Montserrat, González-Farré, Blanca, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., Vivancos, Ana

“…Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with…”
Get full text

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy by Pascual, Tomás, Fernandez-Martinez, Aranzazu, Tanioka, Maki, Dieci, M Vittoria, Pernas, Sonia, Gavila, Joaquin, Guarnieri, Valentina, Cortes, Javier, Villagrasa, Patricia, Chic, Núria, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Griguolo, Gaia, Llombart, Antonio, Conte, Pierfranco, Oliveira, Mafalda, Conte, Benedetta, Paré, Laia, Galvan, Patricia, Carey, Lisa A, Perou, Charles M, Prat, Aleix

“…We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer. The…”
Get full text

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer by Prat, Aleix, Guarneri, Valentina, Pascual, Tomás, Brasó-Maristany, Fara, Sanfeliu, Esther, Paré, Laia, Schettini, Francesco, Martínez, Débora, Jares, Pedro, Griguolo, Gaia, Dieci, Maria Vittoria, Cortés, Javier, Llombart-Cussac, Antonio, Conte, Benedetta, Marín-Aguilera, Mercedes, Chic, Nuria, Puig-Butillé, Joan Anton, Martínez, Antonio, Galván, Patricia, Tsai, Yi-Hsuan, González-Farré, Blanca, Mira, Aurea, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S., Conte, Pierfranco, Perou, Charles M.

“…Both clinical and genomic data independently predict survival and treatment response in early-stage HER2-positive breast cancer. Here we present the…”
Get full text

Gene expression profiles of breast cancer metastasis according to organ site by Brasó‐Maristany, Fara, Paré, Laia, Chic, Nuria, Martínez‐Sáez, Olga, Pascual, Tomás, Mallafré‐Larrosa, Meritxell, Schettini, Francesco, González‐Farré, Blanca, Sanfeliu, Esther, Martínez, Débora, Galván, Patricia, Barnadas, Esther, Salinas, Belinda, Tolosa, Pablo, Ciruelos, Eva, Carcelero, Esther, Guillén, Cecilia, Adamo, Barbara, Moreno, Reinaldo, Vidal, Maria, Muñoz, Montserrat, Prat, Aleix

“…In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of…”
Get full text

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer by Lorman-Carbó, Natàlia, Martínez-Sáez, Olga, Fernandez-Martinez, Aranzazu, Galván, Patricia, Chic, Nuria, Garcia-Fructuoso, Isabel, Rodríguez, Adela, Gómez-Bravo, Raquel, Schettini, Francesco, Blasco, Paula, Castillo, Oleguer, González-Farré, Blanca, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Perou, Charles M., Malumbres, Marcos, Gavilá, Joaquín, Pascual, Tomás, Prat, Aleix, Brasó-Maristany, Fara

“…This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase…”
Get full text

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna by Buus, Richard, Szijgyarto, Zsolt, Schuster, Eugene F., Xiao, Hui, Haynes, Ben P., Sestak, Ivana, Cuzick, Jack, Paré, Laia, Seguí, Elia, Chic, Nuria, Prat, Aleix, Dowsett, Mitch, Cheang, Maggie Chon U.

“…Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to…”
Get full text

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy by Martínez-Sáez, Olga, Pascual, Tomás, Brasó-Maristany, Fara, Chic, Nuria, González-Farré, Blanca, Sanfeliu, Esther, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Anna Belén, Schettini, Francesco, Conte, Benedetta, Vidal, Maria, Adamo, Barbara, Martínez, Antoni, Muñoz, Montserrat, Moreno, Reinaldo, Villagrasa, Patricia, Salvador, Fernando, Ciruelos, Eva M., Faull, Iris, Odegaard, Justin I., Prat, Aleix

“…Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET);…”
Get full text

A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies by Conte, Benedetta, Brasó-Maristany, Fara, Hernández, Adela Rodríguez, Pascual, Tomás, Villacampa, Guillermo, Schettini, Francesco, Vidal Losada, Maria J., Seguí, Elia, Angelats, Laura, Garcia-Fructuoso, Isabel, Gómez-Bravo, Raquel, Lorman-Carbó, Natàlia, Paré, Laia, Marín-Aguilera, Mercedes, Martínez-Sáez, Olga, Adamo, Barbara, Sanfeliu, Esther, Fratini, Beatrice, Falato, Claudette, Chic, Núria, Vivancos, Ana, Villagrasa, Patricia, Staaf, Johan, Parker, Joel S., Perou, Charles M., Prat, Aleix

“…Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial…”
Get full text

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer by Brasó-Maristany, Fara, Sansó, Miriam, Chic, Nuria, Martínez, Débora, González-Farré, Blanca, Sanfeliu, Esther, Ghiglione, Lucio, Carcelero, Esther, Garcia-Corbacho, Javier, Sánchez, Marcelo, Soy, Dolors, Jares, Pedro, Peg, Vicente, Saura, Cristina, Muñoz, Montserrat, Prat, Aleix, Vivancos, Ana

“…The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in…”
Get full text

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data by Díaz-Redondo, Tamara, Lavado-Valenzuela, Rocio, Jimenez, Begoña, Pascual, Tomas, Gálvez, Fernando, Falcón, Alejandro, Alamo, Maria del Carmen, Morales, Cristina, Amerigo, Marta, Pascual, Javier, Sanchez-Muñoz, Alfonso, González-Guerrero, Macarena, Vicioso, Luis, Laborda, Aurora, Ortega, Maria Victoria, Perez, Lidia, Fernandez-Martinez, Aranzazu, Chic, Nuria, Jerez, Jose Manuel, Alvarez, Martina, Prat, Aleix, Ribelles, Nuria, Alba, Emilio

“…Background: Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast…”
Get full text

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy by Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix

“…Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC) according to menopausal status needs a biological explanation. We…”
Get full text

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy by Pascual, Tomás, Fernandez-Martinez, Aranzazu, Agrawal, Yash, Pfefferle, Adam D., Chic, Nuria, Brasó-Maristany, Fara, Gonzàlez-Farré, Blanca, Paré, Laia, Villacampa, Guillermo, Saura, Cristina, Hernando, Cristina, Muñoz, Montserrat, Galván, Patricia, Gonzàlez-Farré, Xavier, Oliveira, Mafalda, Gil-Gil, Miguel, Ciruelos, Eva, Villagrasa, Patricia, Gavilá, Joaquín, Prat, Aleix, Perou, Charles M.

“…In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the…”
Get full text

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer by Pascual, Tomás, Martin, Miguel, Fernández-Martínez, Aranzazu, Paré, Laia, Alba, Emilio, Rodríguez-Lescure, Álvaro, Perrone, Giuseppe, Cortés, Javier, Morales, Serafín, Lluch, Ana, Urruticoechea, Ander, González-Farré, Blanca, Galván, Patricia, Jares, Pedro, Rodriguez, Adela, Chic, Nuria, Righi, Daniela, Cejalvo, Juan Miguel, Tonini, Giuseppe, Adamo, Barbara, Vidal, Maria, Villagrasa, Patricia, Muñoz, Montserrat, Prat, Aleix

“…In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low…”
Get full text